So, the large bowel and gastric findings overlap with FAP, and it is not clear if the gastric polyposis or cancer risk in those with a promoter 1B deletion differs to FAP due to other pathogenic variants. The gene discussed is FAP; the disease is hyperplastic polyposis syndrome.